Zeltiq Aesthetics Inc (ZLTQ) rated Outperform by William Blair
William Blair rated Outperform Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) on 12/20/2011, when the stock price was $12.29. Since
then, Zeltiq Aesthetics Inc has lost 57.36% as of 05/24/2013's recent price of $5.24. If you would have followed this William Blair's recommendation on ZLTQ, you would have lost 57.36% of your investment in 521 days.
ZELTIQ Aesthetics, Inc. (ZELTIQ) is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ?s North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ?s physician customers.
The Equity Research department provides the firm's clients with in-depth investment analysis and investment recommendations. Acting as the company's laboratory for new investment ideas, it specializes in providing investment analysis on quality growth companies. Located together in our Chicago office, our equity analysts currently follow a universe of nearly 360 companies.